Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Российский университет дружбы народов, Москва
Список исп. литературыСкрыть список 1. Вальдоксан (Агомелатин) в терапии тяжелых и умеренных депрессий непсихотического уровня у пациентов психиатрического стационара. Статистический отчет обсервационного исследования «Время». М., 2010. 2. Иванов М.В., Мазо Г.Э. Полифармакотерапевтический подход к лечению резистентных депрессивных состояний. Усовершенствованная медицинская технология. СПб., 2007. 3. Медведев В.Э. Перспективы использования мелатонинергических препаратов в терапии депрессий у пациентов с сердечно-сосудистыми заболеваниями. Психиатр. и психофармакотер. 2010; 3: 19–23. 4. Медведев В.Э., Епифанов А.В. Инновационный метод терапии депрессий у пациентов с ишемической болезнью сердца. Обозрение психиатрии и мед. психологии им. В.М.Бехтерева. 2010; 3: 31–6. 5. Смулевич А.Б. Дифференцированная терапия при депрессиях и коморбидной патологии. Психиатр. и психофармакотер. 2001; 3: 76–9. 6. Цыганков Б.Д., Ялтонская А.В., Филиппских С.В. Вальдоксан (агомелатин) в терапии тяжелых и умеренных депрессий непсихотического уровня (результаты обсервационного исследования). 2011. 7. Ables AZ, Baughman OL. Antidepressants: update on new agents and indications. Am Family Physician 2003; 67: 547–54. 8. Anderson I, Tomenson B. A meta analysis if the efficacy of serotonin reuptake inhibitors compared to tricyclic antidepressants in depression. Neuropsychopharmacol 1994; 10 (Suppl.): 106. 9. Bymaster FP, Dreshfield A, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, hyman serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacol 2001; 25: 871–80. 10. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002; 325: 1332–3. 11. Cheeta S, Schifano F, Oyefeso A et al. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998–2000. The British J Psychiat 2004; 184: 41–7. 12. Cowen PJ. Pharmacological management of treatment-resistant depression. Advances in Psychiatric Treatment 1998; 4: 320–7. 13. Crewe HK, Lennard MS, Tucker GT et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. British J Clin Pharmacol 1992; 34: 262–5. 14. Dardennes R, Berdeaux G, Lafuma A, Fagnani F. Comparison of the cost-effectiveness of milnacipran (a SNRI) with TCAs and SSRIs: a modeling approach. Eur Psychiat 1999; 14 (3): 152–62. 15. Depont F, Rambelomanana S, Puil S et al. Antidepressants: psychiatrists’ opinions and clinical practice. Acta Psychiat Scand 2003; 108: 24–31. 16. Donoghue JM, Taylor DM. Suboptimal use of antidepressants in the treatment of depression. CNS Drugs 2000; 13: 365–3. 17. Donoghue JM, Tylee A. The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. Br J Psychiat 1996; 168: 164–8. 18. Drent M, Singh S, Gorgels AP et al. Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. Am J Respiratory and Critical Care Med 2003; 167: 958–61. 19. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiat 2001; 62 (Suppl. 18): 4–11. 20. Fava M, McGrath PJ, Sheu WP. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J Clin Psychopharmacol 2003; 23 (4): 365–9. 21. Freeman JW, Mundy GR, Beattie RR et al. Cardiac abnormalities in poisoning with tricyclic antidepressants. BMJ 1969; 2: 610–1. 22. Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 2002; 325: 991–9. 23. Gasto C, Navarro V, Marcos T et al. Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharmacol 2003; 23 (1): 21–6. 24. Kasper S, Lemoine P. Comparative efficacy of the antidepressants agomelatine, venlafaxine and sertraline [abstr.]. In: 21st European College of Neuropsycho-pharmacology Congress 2008; Bareelone, Spain. Eur Neuropsychopharmacol 2008; 18: 331–2. 25. Kennedy SH et al. Treating depression effectively. J Clin Psychiat 2004; 78 (Suppl. 3): 44–9. 26. Lôo H, Daléry J, Macher JP, Payen A. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5-HT2C receptors antagonist, in the treatment of major depressive disorders. Encephal 2003; 29 (2): 165–71. 27. Ma Y, Henry JA. The antidotal effect of alpha(1)-acid glycoprotein on amitriptyline toxicity in cardiac myocytes. Toxicol 2001; 169: 133–44. 28. Marshall JB, Forker AD. Cardiovascular effects of tricyclic antidepressant drugs: therapeutic usage, overdose, and management of complications. Am Heart J 1982; 103: 401–14. 29. Parker G. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiat Scand 2002; 106 (3): 168–70. 30. Rochat B, Amey M, Gillet M et al. Identification of three cytochrome P-450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenet 1997; 7: 1–10. 31. Sartorius N, Baghai T, Baldwin D, Brand U. The use and usefulness of antidepressants a technical review of avidance by a tesk forse of the ECNP 2006; 276. 32. Smith D, Dempster C, Glanville J et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. ACP J Club 2002; 137 (3): 101. 33. Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants. Am J of Psychiat 1988; 145: 1478. 34. Vezmar S, Miljkovic B, Vucicevic K et al. Фармакокинетика и клиническая эффективность комбинации флувоксамина и амитриптилина в лечении депрессии. J Pharmacol Sci 2009; 110: 98–104. 35. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003; 23: 58–77.